Repair & Recovery

This page covers what BPC-157 and TB-500 are as synthetic reference materials, how their research mechanisms differ, what the current evidence base shows, and what South African laboratories verify before procurement. All materials discussed are for laboratory and in-vitro research; not for human or veterinary use.

• BPC-157 and TB-500 address distinct points in the repair cascade, each with its own place within a protocol.
• The evidence base for both materials is predominantly preclinical: 35 of the 39 eligible BPC-157 studies in a 2025 systematic review were preclinical.
• Batch-specific CoA documentation covering peptide sequence, HPLC purity, mass spectrometry identity and endotoxin screen ships with each pen and is matched to the batch number before any material enters a protocol.

BPC-157 is a stable gastric pentadecapeptide studied in cell cultures and animal models for reported effects on angiogenesis, collagen synthesis and nitric oxide (NO) signalling. TB-500 is a synthetic fragment related to thymosin β4, examined for its role in actin reorganisation, endothelial cell migration and stem cell recruitment.

A 2025 orthopaedic systematic review identified 39 eligible BPC-157 studies spanning 1993–2024, of which 35 were preclinical [1]. That ratio defines the evidence base: these are research tools for modelling repair pathways at the cellular and preclinical level. Veyvora’s category is built around that distinction, presenting BPC-157 and TB-500 as complementary reference materials for laboratories investigating tissue-repair mechanisms.

Browse the repair and recovery range to compare available batch documentation across the category, or visit Veyvora’s research-peptide catalogue to review the full range of reference materials and supplier quality documentation.

Veyvora supplies BPC-157 and TB-500 together as a single combined research pen, the BPC-157 + TB-500 40 mg pen. The two peptides act through distinct, complementary pathways, which is the rationale for combining them in one pen rather than stocking them as separate SKUs.

BPC-157

BPC-157 is a stable gastric pentadecapeptide investigated across musculoskeletal, gastrointestinal and vascular injury models, with preclinical research examining reported effects on angiogenesis, collagen synthesis, fibroblast proliferation and NO signalling [1]. The 2025 orthopaedic systematic review identified 39 eligible studies spanning 1993–2024, of which 35 were preclinical and one was clinical [1]. Within this catalogue, BPC-157 is a tool for interrogating local tissue resilience, tendon-ligament junction repair and gastrointestinal mucosal healing in cell and animal models.

TB-500

TB-500 is a synthetic fragment related to thymosin β4, studied for its role in actin reorganisation, endothelial cell migration, stem and progenitor cell homing, and anti-fibrotic remodelling. Preclinical models have applied TB-500 to cardiac, dermal, corneal and musculoskeletal repair contexts, with a focus on upstream recruitment and vascularisation signalling rather than localised cytoprotection. A 2026 scoping review on thymosin β4 and related fragments reported promising tissue-repair signals across animal models and identified standardisation as the main open task, with a sparse, methodologically heterogeneous clinical trial base.

These two entities are distinct in primary mechanism and target tissue profile, each with its own role within a research protocol. Formulation details, including the pre-filled solution-pen specification and confirmed purity figures, are read from the batch-specific CoA. Verify a batch against its CoA before use and consult storage and stability guidance to confirm cold-chain requirements for each material.

The evidence base for both BPC-157 and TB-500 is predominantly preclinical, which shapes how laboratory researchers frame protocols and interpret results.

The 2025 orthopaedic systematic review found that 35 of 39 eligible BPC-157 studies were preclinical and one was clinical, with the authors concluding that in-human safety and therapeutic value remain to be established [1]. The 2026 scoping review on thymosin β4 and related fragments reported promising tissue-repair signals across animal models and identified standardisation as the main open task, alongside a sparse, methodologically heterogeneous clinical trial base.

Preclinical findings, such as changes in collagen deposition, angiogenic marker expression and fracture callus quality, describe mechanistic signals in cell and animal models.

HPLC purity reports chromatographic purity; mass spectrometry confirms identity and the endotoxin screen reports contamination, so all three appear in the CoA before any material enters a protocol. The HPLC purity explainer sets out what each method reports.

Researchers who have assessed the repair-range procurement criteria above will typically need one of the following next steps: a deeper mechanistic profile of a single peptide, a structured side-by-side comparison of BPC-157 and TB-500, or a route back to the full catalogue to assess other reference materials.

Individual peptide pages cover the evidence in greater depth than a category overview can. The BPC-157 research page addresses tendon-ligament junction data, gastrointestinal mucosal models and NO pathway modulation in isolation. The TB-500 research page focuses on thymosin β4 biology, cardiac post-infarct repair, wound-closure kinetics and fibrosis markers. A structured BPC-157 versus TB-500 comparison contrasts peptide structure, primary signalling pathways, typical preclinical models and evidence maturity as of 2025–2026 [1].

All pages in this section carry the research-use designation. Browse the repair and recovery range to compare available batch documentation across the category, or visit Veyvora’s research-peptide catalogue to review the full range of reference materials and supplier quality documentation.